

# CITATION REPORT

List of articles citing

**Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients**

**DOI: 10.1111/apt.12721**

**Alimentary Pharmacology and Therapeutics, 2014, 39, 1180-9**

**Source:** <https://exaly.com/paper-pdf/58880622/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
326	Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond. <b>2014</b> , 20, 16811-9		31
325	The natural history of HCV-related cirrhosis and its temporal progression across the different clinical stages. <b>2014</b> , 8, 527-39		5
324	Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. <b>2014</b> , 46 Suppl 5, S197-205		6
323	Scoring systems for 6-month mortality in critically ill cirrhotic patients: a prospective analysis of chronic liver failure - sequential organ failure assessment score (CLIF-SOFA). <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 1056-65	6.1	45
322	The clinical course of cirrhosis: The importance of multistate models and competing risks analysis. <b>2015</b> , 62, 292-302		106
321	Relationship and interaction between serum sodium concentration and portal hemodynamics in patients with cirrhosis. <b>2015</b> , 30, 1635-42		2
320	Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. <b>2015</b> , 7, 607-15		34
319	Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. <b>2015</b> , 13, 2109-17		45
318	Understanding the Complexities of Cirrhosis. <b>2015</b> , 37, 1822-36		28
317	Clinical Evaluation and Prognosis. <b>2015</b> , 33, 515-23		8
316	Cirrhotic Multiorgan Syndrome. <b>2015</b> , 60, 3209-25		28
315	U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. <b>2015</b> , 64, 1680-704		317
314	Natural History of Cirrhosis. <b>2015</b> , 13-20		1
313	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. <b>2015</b> , 13, 1846-1853.e1		45
312	Non-invasive mBage �trois for the prediction of high-risk varices: stepwise algorithm using lok score, liver and spleen stiffness. <b>2015</b> , 35, 317-25		30
311	Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension. <b>2016</b> , 36, 1313-21		20
310	Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. <b>2016</b> , 36, 1765-1773		14

309	Differential visceral blood flow in the hyperdynamic circulation of patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 947-54	6.1	30
308	Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. <b>2016</b> , 151, 130-139.e2		107
307	Prognosis research and risk of bias. <b>2016</b> , 11, 251-60		10
306	Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. <b>2016</b> , 65, S109-S119		43
305	Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study. <b>2016</b> , 64, 2173-2184		140
304	Cancer and liver cirrhosis: implications on prognosis and management. <b>2016</b> , 1, e000042		124
303	Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare. <b>2016</b> , 52, 412-419.e1		14
302	Acute-on-chronic and Decompensated Chronic Liver Failure: Definitions, Epidemiology, and Prognostication. <b>2016</b> , 32, 301-9		10
301	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <b>2016</b> , 150, 1160-1170.e3		171
300	Competing Risks and Prognostic Stages in Cirrhosis. <b>2016</b> , 19-28		
299	Contemporary use of elastography in liver fibrosis and portal hypertension. <b>2017</b> , 37, 235-242		14
298	Prevention and treatment of variceal haemorrhage in 2017. <b>2017</b> , 37 Suppl 1, 104-115		41
297	The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. <b>2017</b> , 7, 42577		14
296	Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1193-1200	6.1	18
295	Hepatitis C Infection: A Systemic Disease. <b>2017</b> , 21, 449-453		21
294	HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study. <b>2017</b> , 49, 1022-1028		13
293	Recent advances in the management of variceal bleeding. <b>2017</b> , 5, 113-126		33
292	Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis. <b>2017</b> , 4, CD008759		20

291	Beta-blockers in patients with advanced liver disease: Has the dust settled?. <b>2017</b> , 23, 1058-1069	18
290	Primary and secondary prophylaxis of esophageal variceal bleeding. <b>2017</b> , 19, 84-89	
289	Neutrophil-to-lymphocyte ratio correlates with proinflammatory neutrophils and predicts death in low model for end-stage liver disease patients with cirrhosis. <b>2017</b> , 23, 155-165	51
288	Cirrhosis Is Associated with Increased Mortality in Patients with Diverticulitis: A Nationwide Cross-Sectional Study. <b>2017</b> , 62, 3149-3155	9
287	Ascites. <b>2017</b> , 475-484	1
286	Reply. <b>2017</b> , 66, 1363-1364	1
285	Factors affecting mortality and resource use for hospitalized patients with cirrhosis: A population-based study. <b>2017</b> , 96, e7782	7
284	History Taking and Physical Examination for the Patient with Liver Disease. <b>2017</b> , 1-16	
283	Teaching echoscopy for the early diagnosis of ascites in cirrhosis: assessment of an objective structured clinical examination (OSCE). <b>2017</b> , 20, 123-126	4
282	Liver Anatomy and Function. <b>2017</b> , 3-11	
281	Risk Stratification with Noninvasive Tools in Patients with Compensated Cirrhosis. <b>2017</b> , 16, 228-236	
280	Beta adrenergic blockade and decompensated cirrhosis. <b>2017</b> , 66, 849-859	95
279	Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. <b>2017</b> , 65, 310-335	936
278	Beta blockers and cirrhosis, 2016. <b>2017</b> , 49, 3-10	50
277	The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. <b>2017</b> , 27, 2600-2609	12
276	Management of Portal Hypertension. <b>2017</b> , 304-335	
275	Prognostic Significance of Hemodynamic and Clinical Stages in the Prediction of Hepatocellular Carcinoma. <b>2017</b> , 51, 285-293	11
274	VARICEAL BLEEDING: UPDATE OF RECOMMENDATIONS FROM THE BRAZILIAN ASSOCIATION OF HEPATOLOGY. <b>2017</b> , 54, 349-355	10

273	Advances and challenges in cirrhosis and portal hypertension. <b>2017</b> , 15, 200		32
272	Patients with liver cirrhosis show worse survival if decompensation occurs later during course of disease than at diagnosis. <b>2018</b> , 53, 475-481		7
271	Liver cirrhosis and cancer: comparison of mortality. <b>2018</b> , 12, 269-276		17
270	Bioelectrical Impedance Analysis-Derived Measurements in Chronic Hepatitis C: Clinical Relevance of Fat-Free Mass and Phase Angle Evaluation. <b>2018</b> , 33, 238-246		10
269	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. <b>2018</b> , 69, 406-460		930
268	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <b>2018</b> , 155, 411-421.e4		201
267	Hepatic and cardiac hemodynamics and systemic inflammation in cirrhosis: It takes three to tango. <b>2018</b> , 68, 887-889		3
266	Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 966-979	6.1	25
265	Association between pre-sarcopenia, sarcopenia, and bone mineral density in patients with chronic hepatitis C. <b>2018</b> , 9, 255-268		24
264	Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis. <b>2018</b> , 38, 1402-1410		7
263	Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. <b>2018</b> , 68, 949-958		75
262	Definitions, Epidemiology and Prognostication of Liver Disease. <b>2018</b> , 75-82		2
261	Local specialty pharmacy and specialty clinic collaboration assists access to hepatitis C direct-acting antivirals. <b>2018</b> , 58, 89-93.e2		10
260	A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. <b>2018</b> , 69, 308-317		84
259	Palliative care in end-stage liver disease: Time to do better?. <b>2018</b> , 24, 961-968		19
258	Acid suppression in patients treated with endoscopic therapy for the management of gastroesophageal varices: a systematic review and meta-analysis. <b>2018</b> , 12, 617-624		7
257	New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. <b>2018</b> , 12, 34-43		45
256	Elevated cardiac troponin T in cirrhotic patients with emergency care admissions: Associations with mortality. <b>2018</b> , 33, 518-523		5

255	Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. <b>2018</b> , 6, 225-237	3
254	Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. <b>2018</b> , 50, 156-162	4
253	The portal hypertension syndrome: etiology, classification, relevance, and animal models. <b>2018</b> , 12, 1-10	52
252	Clinical states of cirrhosis and competing risks. <b>2018</b> , 68, 563-576	158
251	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. <b>2018</b> , 68, 78-88	28
250	The noninvasive diagnosis of esophageal varices and its application in clinical practice. <b>2018</b> , 42, 6-16	11
249	Validation of prognostic scores to predict short-term mortality in patients with acute-on-chronic liver failure. <b>2018</b> , 33, 900-909	14
248	Hepatitis C Virus Clearance in Older Adults. <b>2018</b> , 66, 85-91	4
247	Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. <b>2018</b> , 33, 718-725	24
246	<sup>99m</sup> Tc-Phy portal perfusion index imaging helps predict the severity of hepatitis B virus cirrhosis: a preliminary study. <b>2018</b> , 39, 818-824	1
245	Transient elastography can stratify patients with Child-Pugh A cirrhosis according to risk of early decompensation. <b>2018</b> , 30, 1434-1440	7
244	Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. <b>2018</b> ,	2
243	Primary prevention of bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. <b>2018</b> ,	2
242	Secondary prevention of bleeding in people with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis. <b>2018</b> ,	1
241	Treatment for ascites in people with decompensated liver cirrhosis: a network meta-analysis. <b>2018</b> ,	1
240	Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. <b>2018</b> ,	1
239	Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis. <b>2018</b> ,	2
238	Antibiotic prophylaxis for people with cirrhosis and variceal bleeding. <b>2018</b> ,	1

237	Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and death. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 1271-1281	6.1	17
236	Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them?. <b>2018</b> , 17, 301-315		13
235	Rifaximin has the potential to prevent complications of cirrhosis. <b>2018</b> , 11, 1756284818800307		14
234	Hemoglobin A1c Has Suboptimal Performance to Diagnose and Monitor Diabetes Mellitus in Patients with Cirrhosis. <b>2018</b> , 63, 3498-3508		4
233	Efficacy and Safety of Immunosuppressive Therapy for PBC-AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study. <b>2018</b> , 2018, 1965492		3
232	Neutrophil-to-Lymphocyte Ratio Associates Independently With Mortality in Hospitalized Patients With Cirrhosis. <b>2018</b> , 16, 1786-1791.e1		29
231	Long-term albumin in cirrhosis: is it the ANSWER?. <b>2018</b> , 391, 2391-2392		7
230	Cirrhosis and Portal Hypertension: Staging and Prognosis. <b>2018</b> , 1-13		
229	Development of a novel clinical staging model for cirrhosis using the Nationwide Inpatient Sample. <b>2018</b> , 66, 992-997		4
228	Portal Hypertension and Gastrointestinal Bleeding. <b>2018</b> , 172-181		
227	Clinical Assessment and Management of Portal Hypertension. <b>2018</b> , 35, 153-159		6
226	Ruling out esophageal varices in NAFLD cirrhosis: Can we do without endoscopy?. <b>2018</b> , 69, 769-771		4
225	Portal Hypertension in Cirrhosis. <b>2018</b> , 180-208		
224	Ascites. <b>2018</b> , 127-150		
223	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <b>2019</b> , 39, 127-135		32
222	Acute and Chronic Liver Failure. <b>2019</b> , 159-173		
221	Surgery in Patients with Portal Hypertension. <b>2019</b> , 23, 755-780		5
220	Noncirrhotic Portal Hypertension: Current and Emerging Perspectives. <b>2019</b> , 23, 781-807		14

219	Management of Upper GI Bleeding in Cirrhotic Patients. <b>2019</b> , 163-182		
218	Hepatobiliary Diseases in the Cancer Patient Leading to Critical Illness. <b>2019</b> , 1-26		
217	Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?. <b>2019</b> , 18, 144-156		6
216	Management of HCV Infection in Decompensated Cirrhosis in the Transplantation Setting. <b>2019</b> , 167-182		
215	The prognostic impact of cirrhosis on patients receiving maintenance haemodialysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 75-83	6.1	2
214	Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. <b>2019</b> , 18, 603-610		10
213	Understanding the impact of neurologic complications in patients with cirrhosis. <b>2019</b> , 7, 2050312119832090		2
212	β-blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <b>2019</b> , 393, 1597-1608		160
211	SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. <b>2019</b> , 8,		13
210	Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1421-1430	6.1	17
209	Contemporary Epidemiology of Cirrhosis. <b>2019</b> , 17, 244-253		9
208	Emergency Transjugular Intrahepatic Portosystemic Shunt: an Effective and Safe Treatment for Uncontrolled Variceal Bleeding. <b>2019</b> , 23, 2193-2200		6
207	The combined polymorphisms of interleukin-6-174GG genotype and interleukin-10 ATA haplotype are associated with a poor quality of life in patients with chronic hepatitis C. <b>2019</b> , 28, 1531-1542		6
206	Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort. <b>2019</b> , 26, 666-674		5
205	Variceal Bleeding. <b>2019</b> , 619-644		
204	Predicting Future Complications of Cirrhosis. <b>2019</b> , 18, 9-19		0
203	Future Pharmacological Therapies of Portal Hypertension. <b>2019</b> , 18, 36-48		
202	von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis. <b>2019</b> , 9, e025656		5



201	Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. <b>2019</b> , 9, CD013120	5
200	Common NOD2 Risk Variants as Major Susceptibility Factors for Bacterial Infections in Compensated Cirrhosis. <b>2019</b> , 10, e00002	7
199	Interleukin-10 promoter gene polymorphisms are associated with the first major depressive episode in chronic hepatitis C patients. <b>2019</b> , 43, 417-426	2
198	Clinical Aspects of Alcoholic Liver Disease. <b>2019</b> , 3-21	
197	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <b>2019</b> , 114, 446-452	42
196	Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. <b>2019</b> , 69, 1287-1299	28
195	An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. <b>2019</b> , 13, 293-305	13
194	Burden of liver diseases in the world. <b>2019</b> , 70, 151-171	967
193	Screening and Surveillance of Varices in Patients With Cirrhosis. <b>2019</b> , 17, 26-29	21
192	Granulocyte Colony-Stimulating Factor Use in Decompensated Cirrhosis: Lack of Survival Benefit. <b>2020</b> , 10, 124-134	11
191	Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. <b>2020</b> , 18, 2650-2666	206
190	Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study. <b>2020</b> , 71, 627-642	16
189	Baveno VI and Expanded Baveno VI criteria successfully predicts the absence of high-risk gastro-oesophageal varices in a Chilean cohort. <b>2020</b> , 40, 1427-1434	8
188	Clinical Outcomes of Portosystemic Shunts on the Outcome of Liver Transplantation. <b>2020</b> , 26, 693-701	6
187	Does the Functional Liver Imaging Score Derived from Gadoteric Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?. <b>2020</b> , 294, 98-107	23
186	Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis. <b>2020</b> , 72, 1029-1042	7
185	Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation. <b>2020</b> , 23, 309-318	6
184	Organ Damage and Failure. <b>2020</b> , 289-307	

183	The chances of hepatic resection curing hepatocellular carcinoma. <b>2020</b> , 72, 711-717	15
182	Safety of variceal band ligation in patients with cirrhosis and portal vein thrombosis treated with anticoagulant therapy: A retrospective study. <b>2020</b> , 32, 395-400	6
181	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <b>2021</b> , 19, 1950-1958.e7	8
180	Cirrosis hepática. <b>2020</b> , 13, 297-307	1
179	Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges. <b>2020</b> , 2020, 9609731	3
178	Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension. <b>2020</b> , 14, 1083-1092	6
177	Incidence and Bedside Predictors of the First Episode of Overt Hepatic Encephalopathy in Patients With Cirrhosis. <b>2020</b> , 115, 2017-2025	20
176	NUTRIC and Modified NUTRIC are Accurate Predictors of Outcome in End-Stage Liver Disease: A Validation in Critically Ill Patients with Liver Cirrhosis. <b>2020</b> , 12,	4
175	A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. <b>2020</b> , 10, 17259	1
174	Efficacy and safety of ERCP in patients with gastroesophageal varices. <b>2020</b> , 99, e22051	2
173	Acute Life-Threatening Complications of Portal Hypertension: a Review of Pathophysiology, Incidence, Management, and Cost. <b>2020</b> , 2, 1628-1645	
172	The Presence of Ascites Affects the Predictive Value of HVPG on Early Rebleeding in Patients with Cirrhosis. <b>2020</b> , 2020, 1329857	2
171	Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. <b>2020</b> , 9,	59
170	The predictive value of baseline hepatic venous pressure gradient for variceal rebleeding in cirrhotic patients receiving secondary prevention. <b>2020</b> , 8, 91	5
169	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta-analysis. <b>2020</b> , 40, 1435-1446	22
168	Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease. <b>2020</b> , 35, 1523-1529	0
167	Cost-effectiveness of integrating gut microbiota analysis into hospitalisation prediction in cirrhosis. <b>2020</b> , 2, 79-86	4
166	Granulocyte colony-stimulating factor with or without stem or progenitor cell infusion for people with compensated or decompensated advanced chronic liver disease. <b>2020</b> ,	78

165	Can Macrophages in Cirrhotic Ascites Fluid Predict Clinical Outcome in Spontaneous Bacterial Peritonitis?. <b>2020</b> , 158, 1540-1543	1
164	Evaluation of serum kallistatin level as a predictor of esophageal varices in cirrhotic patients. <b>2020</b> , 56, 21-26	
163	Optimal management of ascites. <b>2020</b> , 40 Suppl 1, 128-135	6
162	A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. <b>2020</b> , 72, 1353-1365	14
161	Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. <b>2020</b> , 1, CD013123	5
160	Precision medicine in variceal bleeding: Are we there yet?. <b>2020</b> , 72, 774-784	13
159	Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements With the Automated Low-Flow Ascites Pump. <b>2020</b> , 26, 651-661	10
158	Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey's discriminant function . <b>2020</b> , 72, 636-642	22
157	Impact of Preexisting Chronic Liver Disease on the Outcome of Patients With COVID-19 Disease. <b>2021</b> , 160, 1893-1894	4
156	Derivation and validation of a simple anthropometric equation to predict fat-free mass in patients with chronic hepatitis C. <b>2021</b> , 40, 1281-1288	3
155	Liver fibrosis: Pathophysiology and clinical implications. <b>2021</b> , 13, e1499	15
154	A Novel Score to Predict Esophageal Varices in Patients with Compensated Advanced Chronic Liver Disease. <b>2021</b> , 66, 2084-2091	4
153	Intraabdominal urokinase in the treatment of loculated infected ascites in cirrhosis. <b>2021</b> , 45, 101486	
152	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <b>2021</b> , 74, 819-828	33
151	Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. <b>2021</b> , 74, 274-282	12
150	Clinical impact of sarcopenia assessment in patients with liver cirrhosis. <b>2021</b> , 15, 377-388	5
149	Presence and type of decompensation affects outcomes in autoimmune hepatitis upon treatment with corticosteroids. <b>2021</b> , 5, 81-90	1
148	Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020. <b>2021</b> , 9, 203-208	2

147	Comparison of Seven Noninvasive Models for Predicting Decompensation and Hospitalization in Patients with Cirrhosis. <b>2021</b> , 66, 4508-4517	1
146	Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients. <b>2021</b> ,	5
145	Hepatic Dysfunction Following Radiotherapy and Management. <b>2021</b> , 303-316	
144	Model for end stage liver disease for prediction of mortality in people with cirrhosis.	
143	Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression. <b>2021</b> , 12, e00299	2
142	Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis. <b>2021</b> , 3, CD013122	5
141	Pathophysiology and Management of Variceal Bleeding. <b>2021</b> , 81, 647-667	0
140	Prevalence, Predictors, and Outcomes of Esophageal iasis in Cirrhosis: An Observational Study With Systematic Re and Meta-Analysis (CANDID-VIEW).. <b>2022</b> , 12, 118-128	0
139	Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment. <b>2021</b> , 51, 517-527	6
138	Isolated bacterial infection without decompensation has no impact on survival of compensated patients with cirrhosis. <b>2021</b> , 41, 1370-1378	5
137	Pathogenese und Progression der Leberzirrhose: aktuelle Perspektiven. <b>2021</b> , 16, 137-148	1
136	Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. <b>2021</b> , 4, CD013121	3
135	Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis. <b>2021</b> , 4, CD013155	4
134	Noninvasive Detection of Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease. <b>2021</b> , 25, 253-289	3
133	[Cirrhosis]. <b>2021</b> , 146, 684-697	
132	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <b>2021</b> ,	1
131	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <b>2021</b> , 28, 1190-1199	3
130	SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. <b>2021</b> , 104, 106367	2

129	Prevention of First Decompensation in Advanced Chronic Liver Disease. <b>2021</b> , 25, 291-310	4
128	Towards a new definition of decompensated cirrhosis. <b>2022</b> , 76, 202-207	9
127	Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. <b>2021</b> , 74, 1362-1372	25
126	Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury. <b>2021</b> , 10,	5
125	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. <b>2021</b> , 10,	2
124	New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. <b>2021</b> , 75 Suppl 1, S14-S26	7
123	Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. <b>2021</b> , 13, 731-746	4
122	Endoscopy in Management of Portal Hypertension.	
121	Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C-Related Advanced Fibrosis and Cirrhosis. <b>2021</b> , 8, 925-935	0
120	Reply to: "Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?". <b>2021</b> , 75, 489-490	0
119	Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations. <b>2021</b> , 7, 261-278	1
118	Falls are common, morbid, and predictable in patients with cirrhosis. <b>2021</b> , 75, 582-588	6
117	Frailty is associated with increased risk of cirrhosis disease progression and death. <b>2021</b> ,	6
116	[Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis]. <b>2021</b> , 78, 152-160	0
115	Baveno-VI clinical staging of cirrhosis under-estimates 5-year survival after variceal bleed in cryptogenic chronic liver disease patients in India. <b>2021</b> , 33, 1232-1234	
114	Comparison of General and Liver-Specific Prognostic Scores in Their Ability to Predict Mortality in Cirrhotic Patients Admitted to the Intensive Care Unit. <b>2021</b> , 2021, 9953106	1
113	Tuberculosis in Cirrhosis - A Diagnostic and Management Conundrum.. <b>2022</b> , 12, 278-286	0
112	Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). <b>2021</b> , 53, 1089-1104	5

111	Baveno VI criteria as a prognostic factor for clinical complications in patients with compensated cirrhosis. <b>2021</b> ,	0
110	CT-derived quantitative liver volumetric parameters for prediction of severe esophageal varices and the risk of first variceal hemorrhage. <b>2021</b> , 144, 109984	2
109	Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. <b>2020</b> , 1, CD013125	8
108	Antibiotic prophylaxis versus placebo or no intervention for people with cirrhosis and variceal bleeding.	2
107	Gastroesophageal Variceal Bleeding Management. <b>2020</b> , 39-66	1
106	Where does TIPS fit in the management of patients with cirrhosis?. <b>2020</b> , 2, 100122	25
105	Characteristics and Discrepancies in Acute-on-Chronic Liver Failure: Need for a Unified Definition. <b>2016</b> , 11, e0146745	30
104	Missed Diagnosis of Liver Cirrhosis Leads to Disparities in Care for Older Patients. <b>2018</b> , 11, 333-339	1
103	Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians. <b>2020</b> , 8, 220-236	3
102	The New Cutoff Value of the Hepatic Venous Pressure Gradient on Predicting Long-Term Survival in Cirrhotic Patients. <b>2019</b> , 34, e223	2
101	Prevention and management of gastroesophageal varices. <b>2018</b> , 24, 20-42	32
100	KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. <b>2020</b> , 26, 83-127	22
99	Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding. <b>2020</b> , 26, 540-553	9
98	Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis. <b>2018</b> , 24, 4606-4614	8
97	Interleukin-6-174G/C polymorphism is associated with a decreased risk of type 2 diabetes in patients with chronic hepatitis C virus. <b>2020</b> , 12, 137-148	2
96	Evaluation of Treatment Response after Endoscopic Variceal Obturation with Abdominal Computed Tomography. <b>2020</b> , 14, 117-124	3
95	Emergency Management of Spontaneous Bacterial Peritonitis - A Clinical Review. <b>2018</b> , 10, e2253	4
94	Nonalcoholic Steatohepatitis - Opportunities and Challenges. <b>2021</b> , 385, 1615-1617	1

- 93 Pediatric non-cirrhotic portal hypertension: Endoscopic outcome and perspectives from developing nations. **2021**, 13, 1269-1288 1
- 92 Endoscopic Band Ligation in Primary Prophylaxis. **2016**, 225-234
- 91 Introduction: Prevention of Decompensation Versus Prevention of First Bleeding. **2016**, 195-204
- 90 (Pre)Primary Prophylaxis: Where Were We and Where Are We Heading?. **2016**, 83-87
- 89 Issues in Trial Design and Areas Needing Further Research. **2016**, 355-363
- 88 Expanded polytetrafluoroethylene (ePTFE)-covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis. 78
- 87 Portal Hypertension: Varices. **2017**, 41-56
- 86 Pretransplant Evaluation and Care. **2018**, 737-752.e5
- 85 Development of 365-day Life Expectancy Models: Application of Machine Learning Methods to a Prospective Study of Critically Ill Cirrhotic Patients (Preprint).
- 84 Impact of sepsis and non-communicable diseases on prognostic models to predict the outcome of hospitalized chronic liver disease patients. **2018**, 10, 944-955
- 83 Intensive Care Tactics for Reducing Gastrointestinal Bleeding in the Context of Portal Hypertension. **2019**, 8, 225-230 1
- 82 Management of Ascites. **2020**, 11-30
- 81 Hepatobiliary Diseases in the Cancer Patient Leading to Critical Illness. **2020**, 893-918
- 80 Hepatobiliary Diseases in the Cancer Patient Leading to Critical Illness. **2020**, 1-25
- 79 Bleeding in portal hypertension. **2020**, 66, e7-e16
- 78 An Update on the Management of Esophageal Variceal Hemorrhage. **2021**, 18, 179-183 0
- 77 Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients. **2021**, 110010 3
- 76 Leberzirrhose und deren Komplikationen. **2020**, 345-375

75	Epidemiology of Varices and Variceal Bleeding in Liver Cirrhosis. <b>2021</b> , 1-11	1
74	Prognostic Assessment of Variceal Bleeding in Liver Cirrhosis. <b>2021</b> , 161-169	
73	Role of Etiology Therapy in Management of Variceal Hemorrhage in Liver Cirrhosis. <b>2021</b> , 41-51	
72	The Gastroenterologist's Guide to Preventive Management of Compensated Cirrhosis. <b>2019</b> , 15, 423-430	2
71	Fatty Liver Disease: Diagnosis and Stratification. <b>2021</b> ,	1
70	Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis. <b>2021</b> ,	13
69	Von Willebrand factor and esophageal varices in children with chronic liver diseases.. <b>2021</b> , 7, 429-436	
68	MAJOR DEPRESSIVE DISORDER IS ASSOCIATED WITH TYPE 2 DIABETES IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION.. <b>2021</b> , 58, 476-482	
67	Identifying Ascites in Patients with Cirrhosis Using Administrative Codes and Diuretic Use: A Multicenter Study.. <b>2022</b> , 1	1
66	HSD17B13 and other liver fat-modulating genes predict development of hepatocellular carcinoma among HCV-positive cirrhotics with and without viral clearance after DAA treatment.. <b>2022</b> , 15, 301	0
65	Balloon Tamponade for the Management of Gastrointestinal Bleeding.. <b>2022</b> ,	0
64	Clinical Outcomes in Patients with Advanced Chronic Liver Disease and Hepatic Venous Pressure Gradient $\geq 10$ mm Hg.. <b>2022</b> , 1	
63	Hassab Operation in a Patient with Autoimmune Liver Cirrhosis. <b>2021</b> , 41-51	
62	UPLC-MS/MS-Based Serum Metabolomics Signature as Biomarkers of Esophagogastric Variceal Bleeding in Patients With Cirrhosis.. <b>2022</b> , 10, 839781	0
61	Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.. <b>2022</b> , 1	
60	Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level . <b>2022</b> , 16, 294	0
59	Predictors of mortality at 28-days in infection associated acute kidney injury in cirrhosis.. <b>2022</b> , 14, 592-601	0
58	Implantation of transjugular intrahepatic portosystemic shunt (TIPS): indication and patient selection.. <b>2022</b> ,	0



57	Care of the Hepatology Patient in the COVID-19 Era.. <b>2022</b> , 1-12	0
56	Aspirin improves transplant-free survival after TIPS implantation in patients with refractory ascites: a retrospective multicentre cohort study.. <b>2022</b> , 1	2
55	RATIONAL FOR CONTINUING TERLIPRESSIN AFTER ENDOSCOPIC VARICEAL LIGATION IN ACUTE VARICEAL HAEMORRHAGE NEEDS FURTHER EVIDENCE: A PILOT STUDY.. <b>2022</b> , 59, 89-96	0
54	The natural history of advanced chronic liver disease defined by transient elastography.. <b>2022</b> ,	0
53	Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis.. <b>2022</b> ,	1
52	Taking a risk-based approach to testing for liver disease in primary care, a step in the right direction.. <b>2022</b> ,	0
51	Combined Pharmacological and Endoscopic Treatment for Worsening Gastroesophageal Varices in Patients with Cirrhosis.. <b>2022</b> , 15, 59-65	
50	Brain magnetic resonance imaging radiomics features associated with hepatic encephalopathy in adult cirrhotic patients.. <b>2022</b> , 1	0
49	Are MELD and MELDNa Still Reliable Tools to Predict Mortality on the Liver Transplant Waiting List?. <b>16</b> , Publish Ahead of Print,	
48	Pathophysiologie der Dekompensation bei Leberzirrhose [Prognose-Scores. <b>2022</b> , 147, 662-668	
47	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. <b>2022</b> , 100513	1
46	Management of varices and variceal hemorrhage in liver cirrhosis: a recent update. <b>2022</b> , 15, 175628482211017	
45	A novel SAVE score to stratify decompensation risk in compensated advanced chronic liver disease: an international multicenter cohort study. <b>2022</b> , Publish Ahead of Print,	0
44	Mastering core recommendations during HEPAtology ROUNDS in advanced chronic liver disease.	
43	Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis.	1
42	HDL-C levels added to the MELD score improves 30-day mortality prediction in Asian patients with cirrhosis. <b>2022</b> , 50, 030006052211093	0
41	The risk of variceal bleeding during endoscopic retrograde cholangiopancreatography. Publish Ahead of Print,	
40	Use of endoscopic band ligation alone and in combination with nonselective beta blockers for prevention of variceal bleeding in ascites patients on the liver transplant waiting list. <b>2022</b> , 24, 42-50	1

- 39 Prognosis of systemic inflammation at an early stage of cirrhosis using the monocyte-to-lymphocyte ratio during malnutrition risk screening: a prospective cohort study.
- 38 Recompensation in cirrhosis: Current evidence and future directions. **2022**,
- 37 Bulevirtide monotherapy for 48 Weeks in hcv patients with compensated cirrhosis and clinically significant portal hypertension. **2022**, ○
- 36 Metabolic-associated fatty liver disease is associated with low muscle mass and strength in patients with chronic hepatitis B. **2022**, 14, 1652-1666 ○
- 35 Liver and spleen stiffness as assessed by vibration controlled transient elastography for diagnosing clinically significant portal hypertension in comparison with other elastography-based techniques in adults with chronic liver disease. **2022**, **2022**, 1
- 34 Assessing the risk of further decompensation and survival in patients with cirrhosis with variceal bleeding as their first decompensation event. **2022**, Publish Ahead of Print, ○
- 33 Diuretics in Cirrhotic Patients with Ascites. **2022**, 167-178 ○
- 32 Im Schockraum. **2022**, 153-222 ○
- 31 Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma. **2022**, 22, ○
- 30 Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy. **2022**, 14, 4647 ○
- 29 Prevention of Further Decompensation in Patients With Ascites. **2022**, 549-562 ○
- 28 Therapies for Alcohol-Related Liver Disease and for Non-Alcoholic Fatty Liver Disease. **2022**, 221-238 ○
- 27 Prevention of Variceal Bleeding and Rebleeding. **2022**, 537-547 ○
- 26 βBlockers to Prevent Decompensation of Cirrhosis in Compensated Patients With Clinically Significant Portal Hypertension. **2022**, 407-418 ○
- 25 Concept of Further Decompensation and Recompensation. **2022**, 523-535 ○
- 24 Clinical Stages and Ordinal Outcomes in Portal Hypertension. **2022**, 15-28 ○
- 23 Evaluation of the Role of Jaundice in the Definition of Decompensation in the Compensated Patients. **2022**, 357-362 ○
- 22 Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascites. ○

- 21 Successful Percutaneous Transhepatic Obliteration Plus Sengstaken-Blakemore Tube Combination Therapy for Recurrent Gastroesophageal Variceal Bleeding: A Case Report. **2023**, ○
- 20 Portal Hypertension: Varices. **2022**, 81-104 ○
- 19 The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study. **2022**, ○
- 18 PPAR $\alpha$ -dependent hepatic macrophage switching acts as a central hub for hUCMSCs-mediated alleviation of decompensated liver cirrhosis in rats. ○
- 17 Position statement of Hepatology Society, Dhaka, Bangladesh on Management of acute variceal bleeding in a resource-limited setting. **2022**, ○
- 16 Automated Machine Learning in Predicting 30-Day Mortality in Patients with Non-Cholestatic Cirrhosis. **2022**, 12, 1930 ○
- 15 Erkrankungen von Leber und Pankreas. **2022**, 475-542 ○
- 14 Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. 29, 61-74 ○
- 13 A novel Chongqing index of post-TIPS survival for predicting survival in Chinese cirrhotic patients after transjugular intrahepatic portosystemic shunt: A multicenter, retrospective study. ○
- 12 Rising incidence, progression and changing patterns of liver disease in Wales 1999-2019. 15, 89-106 ○
- 11 The potential role of machine learning in modelling advanced chronic liver disease. **2022**, ○
- 10 Management of Acute Upper Gastrointestinal Bleeding in Critical Care Transport. **2023**, ○
- 9 Liver and spleen stiffness for the diagnosis of oesophageal varices in adults with chronic liver disease. **2023**, 2023, ○
- 8 Decompensation as initial presentation in patients with liver cirrhosis is associated with an increased risk of future decompensation and mortality. 1-8 ○
- 7 The prognostic impact of acute kidney injury recovery patterns in critically ill patients with cirrhosis. **2023**, 29, 246-258 ○
- 6 Longitudinal changes in bone mineral density are associated with long-term survival in patients with cirrhosis: A proof of concept study. ○
- 5 The impact of transmembrane 6 superfamily 2 (TM6SF2) rs58542926 on liver-related events in patients with advanced chronic liver disease. **2023**, ○
- 4 Update in the Treatment of the Complications of Cirrhosis. **2023**, ○

- 3 Global burden of Liver Disease: 2023 Update. **2023**,
- 2 Introduction. **2024**, 1-6
- 1 Endoscopic ultrasound-guided intraportal injection of autologous bone marrow in patients with decompensated liver cirrhosis: A case series. 15, 655-663